Question 1

Should I switch from Trulicity to Foundayo?

Accepted Answer

It depends on what you are optimizing for. Foundayo (orforglipron) is a once-daily oral tablet with substantially larger weight-loss effect (-11.1% TBWL at 17.2 mg in ATTAIN-1, Wharton 2025 NEJM, PMID 40960239) and a deeper A1C drop in ACHIEVE-1 (Rosenstock 2025 NEJM, PMID 40544435). But Trulicity has documented cardiovascular outcome data (REWIND showed 12% MACE reduction, PMID 31189511) that Foundayo does not yet have. If you have established cardiovascular disease and your A1C is controlled, the evidence base still favors staying on Trulicity. If your priorities are larger weight loss, oral convenience, or avoiding weekly injections, switching to Foundayo is reasonable. Discuss timing and titration with your prescriber — standard practice is to stop Trulicity and start Foundayo at 0.8 mg, climbing the ladder every 4 weeks.

Question 2

Will Foundayo's weight loss exceed what I'd get on Trulicity?

Accepted Answer

Almost certainly. ATTAIN-1 (Wharton 2025 NEJM, PMID 40960239) showed Foundayo 17.2 mg produced -11.1% total body-weight loss at 72 weeks in adults with obesity. Trulicity's weight-loss footprint is much smaller — the AWARD program showed roughly -3 kg (about -3% of body weight) at 52 weeks at the 1.5 mg dose, and even the higher-dose 4.5 mg weekly added only modest additional weight loss. No head-to-head trial exists, but cross-trial magnitudes consistently favor Foundayo by a factor of three or more. The trade-off is daily oral dosing versus a weekly shot and Foundayo's higher rates of GI side effects during titration.

Question 3

Can my child take Foundayo?

Accepted Answer

No. Foundayo is FDA-approved for adults only (≥18 years) under both its 2025 obesity label and the pending T2D indication tied to ACHIEVE-1 (Rosenstock 2025 NEJM, PMID 40544435). Trulicity is the only Lilly GLP-1 with a pediatric label — the FDA expanded its approval to include children ≥10 years with type 2 diabetes based on the AWARD-PEDS trial. If your child needs a GLP-1 for T2D, Trulicity (or Ozempic, which also has pediatric labeling for ages 12+) remains the appropriate choice; Foundayo trials in adolescents are still in earlier-phase development.

Question 4

Does Foundayo replace Trulicity for kidney protection?

Accepted Answer

Not yet. Trulicity has direct evidence in advanced chronic kidney disease from AWARD-7 (Tuttle 2018 Lancet Diabetes Endocrinol, PMID 29910024), which randomized 577 patients with T2D and stage 3-4 CKD to dulaglutide vs insulin glargine and showed non-inferior A1C control with preserved estimated GFR and fewer macroalbuminuria events. Foundayo's CKD program is still maturing — the ATTAIN-1 obesity trial excluded patients with significant renal impairment, and dedicated CKD outcome data has not been published. If kidney protection is a primary treatment goal, Trulicity remains the better-evidenced choice until Foundayo accumulates equivalent renal-endpoint data.

Question 5

Is Foundayo's food restriction the same as Rybelsus?

Accepted Answer

No — and this is a major practical advantage. Rybelsus (oral semaglutide) is a peptide that must be taken on an empty stomach with no more than 4 ounces of plain water, followed by 30 minutes of fasting, or absorption collapses. Foundayo (orforglipron) is a non-peptide small molecule designed to be absorbed without an absorption enhancer like SNAC, so the FDA label permits dosing with or without food and without the 30-minute waiting protocol. This is one of the main reasons Lilly's oral non-peptide pipeline drew so much attention — it removes the daily compliance burden that limits Rybelsus uptake. See the Foundayo prescribing information at DailyMed for the labeled dosing instructions.

Question 6

Are the side effects similar between Foundayo and Trulicity?

Accepted Answer

Both share the GLP-1 class GI side-effect profile — nausea, diarrhea, vomiting, constipation, and decreased appetite — and both carry the FDA boxed warning for thyroid C-cell tumors observed in rodent studies. Foundayo's rates tend to be higher during the 0.8 → 17.2 mg titration window because the dose climb is steeper than Trulicity's 0.75 → 4.5 mg ladder. ATTAIN-1 showed roughly 7-9% discontinuation due to adverse events at the highest Foundayo doses; Trulicity discontinuation in REWIND ran about 5-6%. Slower titration generally helps tolerability for both drugs.

Field	Foundayo	Trulicity
Route & frequency	Oral tablet, once daily	Subcutaneous injection, once weekly
Mechanism	Non-peptide small-molecule GLP-1 receptor agonist	Peptide GLP-1 receptor agonist (Fc-fused dulaglutide)
Approved dose ladder	0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg daily	0.75 → 1.5 → 3.0 → 4.5 mg weekly
Weight loss (max dose)	-11.1% TBWL at 72 wk (ATTAIN-1, 17.2 mg)	~-3 kg at 52 wk (AWARD program, 1.5 mg)
A1C reduction (T2D)	-1.3% to -1.6% at 40 wk (ACHIEVE-1, 17.2 mg)	-1.1% at 26-40 wk (1.5 mg, SUSTAIN-7 active comparator)
FDA-approved indications	Chronic weight management (2025); T2D pending ACHIEVE-1 review	Type 2 diabetes; CV risk reduction in T2D with CVD or risk factors
Cardiovascular outcome trial	Dedicated CVOT pending; no MACE outcome data yet	MACE -12% (REWIND, HR 0.88, p=0.026; n=9,901)
Pediatric indication	Adults only (≥18 years)	Children ≥10 years with T2D (label expansion)
Advanced CKD evidence	Limited data in stage 3-4 CKD	Non-inferior A1C and reduced renal events in stage 3-4 CKD (AWARD-7)

Foundayo vs Trulicity (2026): Lilly's Daily Pill vs Weekly Shot

The verdict

Side-by-side comparison

Frequently asked questions